Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 142

Similar articles for PubMed (Select 14583460)

1.

Critical elements of the immunoglobulin heavy chain gene enhancers for deregulated expression of bcl-2.

Heckman CA, Cao T, Somsouk L, Duan H, Mehew JW, Zhang CY, Boxer LM.

Cancer Res. 2003 Oct 15;63(20):6666-73.

2.

The immunoglobulin heavy-chain gene 3' enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells.

Duan H, Heckman CA, Boxer LM.

Oncogene. 2007 Apr 19;26(18):2635-41. Epub 2006 Oct 16.

PMID:
17043638
3.

NF-kappa B activity is required for the deregulation of c-myc expression by the immunoglobulin heavy chain enhancer.

Kanda K, Hu HM, Zhang L, Grandchamps J, Boxer LM.

J Biol Chem. 2000 Oct 13;275(41):32338-46.

4.

NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells.

Heckman CA, Mehew JW, Boxer LM.

Oncogene. 2002 May 30;21(24):3898-908.

5.

Regulation of Bcl-2 expression by C/EBP in t(14;18) lymphoma cells.

Heckman CA, Wheeler MA, Boxer LM.

Oncogene. 2003 Sep 11;22(39):7891-9.

PMID:
12970736
6.

NF-kappa B and Oct-2 synergize to activate the human 3' Igh hs4 enhancer in B cells.

Sepulveda MA, Emelyanov AV, Birshtein BK.

J Immunol. 2004 Jan 15;172(2):1054-64.

7.
9.

A bcl-2/IgH antisense transcript deregulates bcl-2 gene expression in human follicular lymphoma t(14;18) cell lines.

Capaccioli S, Quattrone A, Schiavone N, Calastretti A, Copreni E, Bevilacqua A, Canti G, Gong L, Morelli S, Nicolin A.

Oncogene. 1996 Jul 4;13(1):105-15.

PMID:
8700536
10.
11.

Deregulated PAX-5 transcription from a translocated IgH promoter in marginal zone lymphoma.

Morrison AM, Jäger U, Chott A, Schebesta M, Haas OA, Busslinger M.

Blood. 1998 Nov 15;92(10):3865-78.

12.

A-Myb up-regulates Bcl-2 through a Cdx binding site in t(14;18) lymphoma cells.

Heckman CA, Mehew JW, Ying GG, Introna M, Golay J, Boxer LM.

J Biol Chem. 2000 Mar 3;275(9):6499-508.

13.

Oct transcription factors mediate t(14;18) lymphoma cell survival by directly regulating bcl-2 expression.

Heckman CA, Duan H, Garcia PB, Boxer LM.

Oncogene. 2006 Feb 9;25(6):888-98.

PMID:
16186795
14.

Regulation of 3' IgH enhancers by a common set of factors, including kappa B-binding proteins.

Michaelson JS, Singh M, Snapper CM, Sha WC, Baltimore D, Birshtein BK.

J Immunol. 1996 Apr 15;156(8):2828-39.

PMID:
8609402
15.
16.

Molecular mechanisms of transcriptional control of bcl-2 and c-myc in follicular and transformed lymphoma.

Arcinas M, Heckman CA, Mehew JW, Boxer LM.

Cancer Res. 2001 Jul 1;61(13):5202-6.

18.

T-cell activation leads to poor activation of the HIV-1 clade E long terminal repeat and weak association of nuclear factor-kappaB and NFAT with its enhancer region.

Lemieux AM, Paré ME, Audet B, Legault E, Lefort S, Boucher N, Landry S, van Opijnen T, Berkhout B, Naghavi MH, Tremblay MJ, Barbeau B.

J Biol Chem. 2004 Dec 17;279(51):52949-60. Epub 2004 Oct 1.

19.

The Ig heavy chain 3' end confers a posttranscriptional processing advantage to Bcl-2-IgH fusion RNA in t(14;18) lymphoma.

Petrovic AS, Young RL, Hilgarth B, Ambros P, Korsmeyer SJ, Jaeger U.

Blood. 1998 May 15;91(10):3952-61.

20.

CREB proteins function as positive regulators of the translocated bcl-2 allele in t(14;18) lymphomas.

Ji L, Mochon E, Arcinas M, Boxer LM.

J Biol Chem. 1996 Sep 13;271(37):22687-91.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk